PR91756

BOSTON, Sept. 20, 2021 /PRNewswire=KYODO JBN/

Qynapse Inc., a medical technology company commercializing an AI-powered

neuroimaging software platform for central nervous system (CNS) disorders,

unveils a full rebrand including new logo and a complete website redesign,

intended to better reflect the company's strategic vision, focus and its

commitment to excellence.

The company has placed patient centricity at the core of its rebranding

strategy, as Qynapse is striving to offer tools and solutions that help

clinicians, payers and pharma get the most out of neuroimaging, with the goal

of improving measurement precision, patient outcomes and quality of life for

CNS diseases.

"Before the inception of Qynapse in 2015, we envisioned a future where

neuroimaging AI was widely accepted and adopted as a critical solution for both

clinical routine and clinical trials. Today, major steps have been achieved

towards that vision. We are excited to launch our new brand identity that

better reflects the organization Qynapse has become, committed to bringing

game-changing technology to serve a brighter and more accurate future of

diagnosis and treatment for patients with brain disorders," said Qynapse CEO,

Olivier Courreges.

Qynapse's extensive rebranding initiative stems from some important milestones

that the company has reached in the past year. Tackling new global markets such

as Asia Pacific while maintaining a strong focus in Europe and North America

has reinforced Qynapse's stance as a neuroscience industry leader.

Qynapse continues to pave the way towards more accurate, more reliable

screening and monitoring of CNS disease in both clinical routine settings and

clinical trial applications. Together, with its world-renowned team of

scientific and clinical partners, Qynapse has developed one of the largest

datasets of proprietary

algorithms providing over 200 measures of neurodegeneration and

neuroinflammation, to rapidly, accurately and objectively analyze and interpret

brain scans.

"As an industry, our thinking has evolved. AI is now a critical partner with

humans to drive impactful change across the healthcare ecosystem. For

healthcare providers, payers, pharma and, above all, patients, we aim to bring

ground-breaking peace of mind by providing results they can trust, and our new

brand identity  makes this motivation shine through. It also reflects our

long-term vision, to combine imaging data together with other biomarkers and

patient modalities to positively impact clinical trial outcomes and facilitate

decision making across the CNS care continuum," concluded Matt Ullum, Chief

Commercial Officer at Qynapse.

Visit the new Qynapse website: www.qynapse.com  

About Qynapse Inc.:

Qynapse is a medical technology company commercializing an AI-powered and

proprietary neuroimaging software platform that creates the potential for

earlier clinical precision on the frontlines of CNS disease.

Qynapse's flagship solution, QyScore(R), FDA-Cleared and CE-Marked, combines

MRI scans and AI to produce rapid, actionable insights, adding the potential

for more precise and objective brain scan analysis. Qynapse's predictive AI

technology, QyPredict(R), available for research-use-only, has the potential to

predict disease trajectory and improve targeted patient selection in clinical

trials.

Qynapse is headquartered in France, in the US and in Canada.

ysalledechou@qynapse.com

Logo- https://mma.prnewswire.com/media/1628911/QYNAPSE_Logo.jpg

SOURCE: QYNAPSE